188 related articles for article (PubMed ID: 8702663)
1. Cisplatin and adriamycin resistance are associated with MutLalpha and mismatch repair deficiency in an ovarian tumor cell line.
Drummond JT; Anthoney A; Brown R; Modrich P
J Biol Chem; 1996 Aug; 271(33):19645-8. PubMed ID: 8702663
[TBL] [Abstract][Full Text] [Related]
2. Contribution of human mlh1 and pms2 ATPase activities to DNA mismatch repair.
Tomer G; Buermeyer AB; Nguyen MM; Liskay RM
J Biol Chem; 2002 Jun; 277(24):21801-9. PubMed ID: 11897781
[TBL] [Abstract][Full Text] [Related]
3. hMLH1 expression and cellular responses of ovarian tumour cells to treatment with cytotoxic anticancer agents.
Brown R; Hirst GL; Gallagher WM; McIlwrath AJ; Margison GP; van der Zee AG; Anthoney DA
Oncogene; 1997 Jul; 15(1):45-52. PubMed ID: 9233776
[TBL] [Abstract][Full Text] [Related]
4. Dimerization of MLH1 and PMS2 limits nuclear localization of MutLalpha.
Wu X; Platt JL; Cascalho M
Mol Cell Biol; 2003 May; 23(9):3320-8. PubMed ID: 12697830
[TBL] [Abstract][Full Text] [Related]
5. Human colon cancer cells surviving high doses of cisplatin or oxaliplatin in vitro are not defective in DNA mismatch repair proteins.
Sergent C; Franco N; Chapusot C; Lizard-Nacol S; Isambert N; Correia M; Chauffert B
Cancer Chemother Pharmacol; 2002 Jun; 49(6):445-52. PubMed ID: 12107548
[TBL] [Abstract][Full Text] [Related]
6. Nuclear import of human MLH1, PMS2, and MutLalpha: redundancy is the key.
Leong V; Lorenowicz J; Kozij N; Guarné A
Mol Carcinog; 2009 Aug; 48(8):742-50. PubMed ID: 19148896
[TBL] [Abstract][Full Text] [Related]
7. Decreased expression of the DNA mismatch repair gene Mlh1 under hypoxic stress in mammalian cells.
Mihaylova VT; Bindra RS; Yuan J; Campisi D; Narayanan L; Jensen R; Giordano F; Johnson RS; Rockwell S; Glazer PM
Mol Cell Biol; 2003 May; 23(9):3265-73. PubMed ID: 12697826
[TBL] [Abstract][Full Text] [Related]
8. Activity of a trinuclear platinum complex in human ovarian cancer cell lines sensitive and resistant to cisplatin: cytotoxicity and induction and gene-specific repair of DNA lesions.
Colella G; Pennati M; Bearzatto A; Leone R; Colangelo D; Manzotti C; Daidone MG; Zaffaroni N
Br J Cancer; 2001 May; 84(10):1387-90. PubMed ID: 11355952
[TBL] [Abstract][Full Text] [Related]
9. Contributions by MutL homologues Mlh3 and Pms2 to DNA mismatch repair and tumor suppression in the mouse.
Chen PC; Dudley S; Hagen W; Dizon D; Paxton L; Reichow D; Yoon SR; Yang K; Arnheim N; Liskay RM; Lipkin SM
Cancer Res; 2005 Oct; 65(19):8662-70. PubMed ID: 16204034
[TBL] [Abstract][Full Text] [Related]
10. Mismatch repair and treatment resistance in ovarian cancer.
Helleman J; van Staveren IL; Dinjens WN; van Kuijk PF; Ritstier K; Ewing PC; van der Burg ME; Stoter G; Berns EM
BMC Cancer; 2006 Jul; 6():201. PubMed ID: 16879751
[TBL] [Abstract][Full Text] [Related]
11. The cellular basis of the efficacy of the trinuclear platinum complex BBR 3464 against cisplatin-resistant cells.
Perego P; Gatti L; Caserini C; Supino R; Colangelo D; Leone R; Spinelli S; Farrell N; Zunino F
J Inorg Biochem; 1999 Oct; 77(1-2):59-64. PubMed ID: 10626355
[TBL] [Abstract][Full Text] [Related]
12. Mutations within the hMLH1 and hPMS2 subunits of the human MutLalpha mismatch repair factor affect its ATPase activity, but not its ability to interact with hMutSalpha.
Räschle M; Dufner P; Marra G; Jiricny J
J Biol Chem; 2002 Jun; 277(24):21810-20. PubMed ID: 11948175
[TBL] [Abstract][Full Text] [Related]
13. Down-regulation of DNA mismatch repair proteins in human and murine tumor spheroids: implications for multicellular resistance to alkylating agents.
Francia G; Green SK; Bocci G; Man S; Emmenegger U; Ebos JM; Weinerman A; Shaked Y; Kerbel RS
Mol Cancer Ther; 2005 Oct; 4(10):1484-94. PubMed ID: 16227397
[TBL] [Abstract][Full Text] [Related]
14. Apoptosis and mutation in the murine small intestine: loss of Mlh1- and Pms2-dependent apoptosis leads to increased mutation in vivo.
Sansom OJ; Bishop SM; Court H; Dudley S; Liskay RM; Clarke AR
DNA Repair (Amst); 2003 Sep; 2(9):1029-39. PubMed ID: 12967659
[TBL] [Abstract][Full Text] [Related]
15. Alterations in PMS2, MSH2 and MLH1 expression in human prostate cancer.
Chen Y; Wang J; Fraig MM; Henderson K; Bissada NK; Watson DK; Schweinfest CW
Int J Oncol; 2003 May; 22(5):1033-43. PubMed ID: 12684669
[TBL] [Abstract][Full Text] [Related]
16. Loss of DNA mismatch repair in acquired resistance to cisplatin.
Aebi S; Kurdi-Haidar B; Gordon R; Cenni B; Zheng H; Fink D; Christen RD; Boland CR; Koi M; Fishel R; Howell SB
Cancer Res; 1996 Jul; 56(13):3087-90. PubMed ID: 8674066
[TBL] [Abstract][Full Text] [Related]
17. Mismatch repair gene PMS2: disease-causing germline mutations are frequent in patients whose tumors stain negative for PMS2 protein, but paralogous genes obscure mutation detection and interpretation.
Nakagawa H; Lockman JC; Frankel WL; Hampel H; Steenblock K; Burgart LJ; Thibodeau SN; de la Chapelle A
Cancer Res; 2004 Jul; 64(14):4721-7. PubMed ID: 15256438
[TBL] [Abstract][Full Text] [Related]
18. Multiple mutations are common at mouse Aprt in genotoxin-exposed mismatch repair deficient cells.
Shin CY; Mellon I; Turker MS
Oncogene; 2002 Mar; 21(11):1768-76. PubMed ID: 11896608
[TBL] [Abstract][Full Text] [Related]
19. A CRM1-dependent nuclear export pathway is involved in the regulation of MutLα subcellular localization.
Brieger A; Adam R; Passmann S; Plotz G; Zeuzem S; Trojan J
Genes Chromosomes Cancer; 2011 Feb; 50(2):59-70. PubMed ID: 21064154
[TBL] [Abstract][Full Text] [Related]
20. Expression of the DNA mismatch repair proteins hMLH1 and hPMS2 in normal human tissues.
Fink D; Nebel S; Aebi S; Zheng H; Kim HK; Christen RD; Howell SB
Br J Cancer; 1997; 76(7):890-3. PubMed ID: 9328148
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
